Jurida, Gabor
Amgen (United States)
2 papers on CoChatORCID 0009-0000-8003-1269
Most cited papers
- Verified
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., et al. (2024) · Cancer Discovery
Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers
Cited by 125
- Verified
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Dorff, T., Horvath, L. G., Autio, K., Bernard-Tessier, A., Rettig, M. B., Machiels, J.-P., Bilen, M. A., Lolkema, M. P., Adra, N., Rottey, S., et al. (2024) · Clinical Cancer Research
Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors
Cited by 76
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free